In the study by Boysen et al. of CLL patients, the plasma level of CD52+ MVs was low after three months of ibrutinib treatment; this might reflect a decrease in the total number of tumor cells after response to ibrutinib [45]. This evidence concerns the gene CD52 and B-cell chronic lymphocytic leukemia.